Literature DB >> 24566772

Is prevention a realistic goal for schizophrenia?

Christian Kohler1, Karin E Borgmann-Winter, Irene Hurford, Eli Neustadter, James Yi, Monica E Calkins.   

Abstract

Over the past 2 decades, increased efforts have focused on identifying those at genetic or clinical risk for psychosis and promoting interventions that may alter the onset or trajectory of schizophrenia. We review studies published between 2010-2013 that: (1) investigate at-risk states for psychosis in larger epidemiological studies; (2) identify causes of certain clinical presentations of the schizophrenia phenotype and (3) investigate focused and multidisciplinary approaches to treat early clinical symptoms. The article places these recent studies within the context of prior research and the concept of potential measures to prevent or ameliorate the onset of psychosis.

Entities:  

Mesh:

Year:  2014        PMID: 24566772     DOI: 10.1007/s11920-014-0439-y

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  74 in total

1.  Cognitive changes following antidepressant or antipsychotic treatment in adolescents at clinical risk for psychosis.

Authors:  Christopher R Bowie; Danielle McLaughlin; Ricardo E Carrión; Andrea M Auther; Barbara A Cornblatt
Journal:  Schizophr Res       Date:  2012-02-28       Impact factor: 4.939

Review 2.  The psychosis high-risk state: a comprehensive state-of-the-art review.

Authors:  Paolo Fusar-Poli; Stefan Borgwardt; Andreas Bechdolf; Jean Addington; Anita Riecher-Rössler; Frauke Schultze-Lutter; Matcheri Keshavan; Stephen Wood; Stephan Ruhrmann; Larry J Seidman; Lucia Valmaggia; Tyrone Cannon; Eva Velthorst; Lieuwe De Haan; Barbara Cornblatt; Ilaria Bonoldi; Max Birchwood; Thomas McGlashan; William Carpenter; Patrick McGorry; Joachim Klosterkötter; Philip McGuire; Alison Yung
Journal:  JAMA Psychiatry       Date:  2013-01       Impact factor: 21.596

3.  Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

Authors:  Deepak Cyril D'Souza; Walid Michel Abi-Saab; Steven Madonick; Kimberlee Forselius-Bielen; Anne Doersch; Gabriel Braley; Ralitza Gueorguieva; Thomas B Cooper; John Harrison Krystal
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

4.  Axis I diagnoses and transition to psychosis in clinical high-risk patients EPOS project: prospective follow-up of 245 clinical high-risk outpatients in four countries.

Authors:  Raimo K R Salokangas; Stephan Ruhrmann; Heinrich Graf von Reventlow; Markus Heinimaa; Tanja Svirskis; Tiina From; Sinikka Luutonen; Georg Juckel; Don Linszen; Peter Dingemans; Max Birchwood; Paul Patterson; Frauke Schultze-Lutter; Joachim Klosterkötter
Journal:  Schizophr Res       Date:  2012-03-31       Impact factor: 4.939

5.  Identification of young people at risk of psychosis: validation of Personal Assessment and Crisis Evaluation Clinic intake criteria.

Authors:  L J Phillips; A R Yung; P D McGorry
Journal:  Aust N Z J Psychiatry       Date:  2000-11       Impact factor: 5.744

6.  Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.

Authors:  G Paul Amminger; Miriam R Schäfer; Konstantinos Papageorgiou; Claudia M Klier; Sue M Cotton; Susan M Harrigan; Andrew Mackinnon; Patrick D McGorry; Gregor E Berger
Journal:  Arch Gen Psychiatry       Date:  2010-02

7.  Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome.

Authors:  Patrick D McGorry; Barnaby Nelson; Lisa J Phillips; Hok Pan Yuen; Shona M Francey; Annette Thampi; Gregor E Berger; G Paul Amminger; Magenta B Simmons; Daniel Kelly; Grad Dip; Andrew D Thompson; Alison R Yung
Journal:  J Clin Psychiatry       Date:  2012-11-27       Impact factor: 4.384

8.  Glycine treatment of the risk syndrome for psychosis: report of two pilot studies.

Authors:  Scott W Woods; Barbara C Walsh; Keith A Hawkins; Tandy J Miller; John R Saksa; Deepak C D'Souza; Godfrey D Pearlson; Daniel C Javitt; Thomas H McGlashan; John H Krystal
Journal:  Eur Neuropsychopharmacol       Date:  2012-10-22       Impact factor: 4.600

9.  The "close-in" or ultra high-risk model: a safe and effective strategy for research and clinical intervention in prepsychotic mental disorder.

Authors:  Patrick D McGorry; Alison R Yung; Lisa J Phillips
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

Review 10.  Prevalence of anti-N-methyl-D-aspartate (NMDA) receptor [corrected] antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis.

Authors:  T A Pollak; R McCormack; M Peakman; T R Nicholson; A S David
Journal:  Psychol Med       Date:  2013-12-13       Impact factor: 7.723

View more
  1 in total

Review 1.  Progress and Future Directions in Research on the Psychosis Prodrome: A Review for Clinicians.

Authors:  Kristen A Woodberry; Daniel I Shapiro; Caitlin Bryant; Larry J Seidman
Journal:  Harv Rev Psychiatry       Date:  2016 Mar-Apr       Impact factor: 3.732

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.